Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03920267
Registration number
NCT03920267
Ethics application status
Date submitted
27/03/2019
Date registered
18/04/2019
Date last updated
28/09/2023
Titles & IDs
Public title
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
Query!
Scientific title
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Query!
Secondary ID [1]
0
0
2018-003471-35
Query!
Secondary ID [2]
0
0
IM011-074
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BMS-986165
Experimental: BMS-986165 Dose 1 -
Experimental: BMS-986165 Dose 2 -
Experimental: BMS-986165 Dose 3 -
Treatment: Drugs: BMS-986165
Specified dose on specified days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with Adverse Events (AEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 30 days after last treatment dose (approximately 178 weeks)
Query!
Primary outcome [2]
0
0
Number of participants with Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 30 days after last treatment dose (approximately 178 weeks)
Query!
Primary outcome [3]
0
0
Number of participants with AEs leading to discontinuation
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 30 days after last treatment dose (approximately 178 weeks)
Query!
Primary outcome [4]
0
0
Number of participants with abnormal change from baseline in laboratory measurements over time
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 30 days after last treatment dose (approximately 178 weeks)
Query!
Primary outcome [5]
0
0
Number of participants with abnormal change from baseline in vital signs over time
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to 30 days after last treatment dose (approximately 178 weeks)
Query!
Eligibility
Key inclusion criteria
- Completion of SLE Study (NCT03252587) through the protocol-required treatment period,
and currently receiving blinded study drug. Note: If a subject is not receiving
blinded study drug due to exceptional circumstances (eg, missed investigational
product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may
be allowed to enroll with approval from the BMS Clinical Trial Physician or designee.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any disease or medical condition that, in the opinion of the investigator, would make
the subject unsuitable for this study, would interfere with the interpretation of
subject safety or study results, or considered unsuitable by the investigator for any
other reason
- Evidence of active tuberculosis (TB)
Other protocol-defined inclusion/exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/03/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
261
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Oklahoma
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Buenos Aires
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Santa FE
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Tucuman
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Caba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Cordoba
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Mendoza
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Bahia
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Goias
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Minas Gerais
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Parana
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
RIO Grande DO SUL
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
SAO Paulo
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Sao Paulo
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Alberta
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Ontario
Query!
Country [28]
0
0
Colombia
Query!
State/province [28]
0
0
Barranquilla
Query!
Country [29]
0
0
Colombia
Query!
State/province [29]
0
0
Bogot
Query!
Country [30]
0
0
Colombia
Query!
State/province [30]
0
0
Chia
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Zipaquira
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Debrecen
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Gyula
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Szeged
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Chiba
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Fukuoka
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Hokkaido
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Miyagi
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Tochigi
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Tokyo
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Seoul
Query!
Country [42]
0
0
Korea, Republic of
Query!
State/province [42]
0
0
Suwon
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Distrito Federal
Query!
Country [44]
0
0
Mexico
Query!
State/province [44]
0
0
Guanajuato
Query!
Country [45]
0
0
Mexico
Query!
State/province [45]
0
0
Jalisco
Query!
Country [46]
0
0
Mexico
Query!
State/province [46]
0
0
Nuevo LEON
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
San Luis Potosi
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Bydgoszcz
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Koscian
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Krakow
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Krak
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Lublin
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Poznan
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Sosnowiec
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Warsaw
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Warszawa
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Wroclaw
Query!
Country [58]
0
0
Romania
Query!
State/province [58]
0
0
Brasov
Query!
Country [59]
0
0
Romania
Query!
State/province [59]
0
0
Galati
Query!
Country [60]
0
0
Romania
Query!
State/province [60]
0
0
Ramnicu Valcea
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Ekaterinburg
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Kemerovo
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Novosibirsk
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Orenburg
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Saint - Petersburg
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Smolensk
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
St. Petersburg
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Vladimir
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Yaroslavl
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Malaga
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Sabadell
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Sevilla
Query!
Country [73]
0
0
Taiwan
Query!
State/province [73]
0
0
Taichung
Query!
Country [74]
0
0
Taiwan
Query!
State/province [74]
0
0
Taipei City
Query!
Country [75]
0
0
Taiwan
Query!
State/province [75]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main objective of the trial is to characterize the long-term safety and tolerability of
BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03920267
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03920267
Download to PDF